Administrative data were used to establish a multi-center cohort of 1,686 children treated acute myeloidleukemia (AML). The cohort assembly process, which included myeloid leukemia ICD-9 discharge diagnosis codes and manual review of induction chemotherapy, was validated by chart review at a single institution. This cohort is representative for US and provides a reliable source for future comparative effectiveness and clinical epidemiology studies in pediatric AML.
F.15 Development of a new information system/databases
COBISS.SI-ID: 669356This study is the first comprehensive analyses of the US national trends in pediatric AML induction mortality and resource utilization. Using resource utilization data as a proxy for adverse events, adverse event rates reported on clinical trials substantially underestimated the clinical toxicities of all pediatric AML induction regimens.
F.22 Improvement to existing health/diagnostic methods/procedures
COBISS.SI-ID: 668844We aimed to describe the pharmacoepidemiology of rituximab use in children and to estimate the frequency of infectious events within a 1-year period after rituximab exposure. This was a retrospective cohort study of patients who received rituximab at 1 of 42 children's hospitals contributing data to the Pediatric Health Information System. A total of 2875 patients with 4639 rituximab admissions were identified. The rate of rituximab admissions increased from 3 to 185 per 100.000 admissions per year over the study interval. During the 1-year follow-up period, 463 patients (16%) died, 6.1% were diagnosed with sepsis and 2.0% with septic shock. The frequency of sepsis ranged from 2.4% in patients with autoimmune diseases to 12.2% in those with primary immunodeficiencies. Three patients were assigned an ICD-9-CM discharge diagnosis code for Pneumocystis joroveci pneumonia, 1 patient was assigned an ICD-9-CM discharge diagnosis code for hepatitis B, and 1 patient was assigned an ICD-9-CM discharge diagnosis code for progressive multifocal leukoencephalopathy. Based on ICD-9-CM code data, the rates of sepsis and other life-threatening infections after rituximab exposure vary depending on the underlying condition. Based on surveillance of infection using ICD-9-CM diagnosis codes, the rates of opportunistic infections appear to be low.
F.02 Acquisition of new scientific knowledge
COBISS.SI-ID: 669100